Company: Canntab Therapeutics Limited
CEO: Jeff Renwick, CEO & Richard Goldstein, CFO
Canntab Therapeutics Limited Interview
For a PDF of the Slide Presentations Click Here
We have a clear vision to become a leader in oral dosage cannabis, with unique products that offer advantages to the medical community, patients, adult use consumers and governments.
• Clear and Sustainable Competitive Advantage Through Robust Intellectual Property with 13 patents pending.
• Well financed, publicly traded on the CSE (:PILL).
• We’ve created valuable licensing and joint venture deals in Canada and international markets, such as Australia and Germany.
• We’re launching our first two products under the 420 Therapeutics brand in the coming months.
• Along with our Canadian licensing partner, Emblem, we’ve received Health Canada approval for the development and clinical trials of our breakthrough Extended Release (XR) Tablets.
• Robust new product development, including the development of 420 Therapeutics, with the goal to be a leader in the wellness category.
• Established Leadership with a Track Record of Driving Value.